ResearchOutcomes of Bispecific Antibodies After CAR T-Cell Failure for Large B-cell Lymphoma- Results from the ABC Consortium
ResearchOutcomes for CART as 2L vs 3L vs 4L or Beyond in Aggressive B-cell Lymphoma: Real World Evidence from the ABC Consortium
ResearchFive-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma
ResearchImmunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation
ResearchDiffuse large B-cell lymphoma involving osseous sites: utility of response assessment by PET/CT and good longterm outcomes
ResearchPolatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study
ResearchLoss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas
ResearchMatched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP
ResearchBudget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USA
ResearchDurable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study
ResearchCost-effectiveness analysis of mosunetuzumab for treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in the United States
ResearchCHRONOS-4: phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma
ResearchMolecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with or mutations: an open label phase II study
ResearchLow incidence of cardiotoxicity in patients with non-Hodgkin lymphoma receiving EPOCH after prior anthracycline exposure
ResearchOutcomes of Patients with Positive Interim Positron Emission Tomography (PET) Continuing ABVD in the Clinical Setting